Analysts’ Top Healthcare Picks: Lantheus (LNTH), Bicycle Therapeutics (BCYC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lantheus (LNTH – Research Report), Bicycle Therapeutics (BCYC – Research Report) and Elevation Oncology (ELEV – Research Report) with bullish sentiments.

Lantheus (LNTH)

JMP Securities analyst David Turkaly reiterated a Buy rating on Lantheus today and set a price target of $100.00. The company’s shares closed last Thursday at $78.18.

According to TipRanks.com, Turkaly has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.8% and a 38.9% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lantheus with a $97.14 average price target.

See today’s best-performing stocks on TipRanks >>

Bicycle Therapeutics (BCYC)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Bicycle Therapeutics, with a price target of $32.00. The company’s shares closed last Thursday at $24.69.

According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.4% and a 35.3% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Iovance Biotherapeutics, and Allogene Therapeutics.

Currently, the analyst consensus on Bicycle Therapeutics is a Strong Buy with an average price target of $44.71.

Elevation Oncology (ELEV)

JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Elevation Oncology today and set a price target of $7.00. The company’s shares closed last Thursday at $3.82.

According to TipRanks.com, Tuerkcan is a 4-star analyst with an average return of 6.0% and a 36.1% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Crispr Therapeutics AG, and Intellia Therapeutics.

Elevation Oncology has an analyst consensus of Strong Buy, with a price target consensus of $7.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LNTH:

• Lantheus Stockholders Approve Key Governance and Compensation Plans
• Lantheus price target raised to $99 from $95 at B. Riley
• Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
• Lantheus director sells $6.13M in common stock
• Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024